Literature DB >> 2943533

Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%.

M Cleman, C C Jaffee, D Wohlgelernter.   

Abstract

Catheter balloon inflation performed during percutaneous transluminal coronary angioplasty (PTCA) results in temporary interruption of coronary blood flow and subsequent myocardial ischemia. This produces transient but profound regional left ventricular dysfunction. In an effort to mitigate this inflation-related dysfunction, oxygenated Fluosol DA 20%, a perfluorochemical oxygen transport fluid, was infused distal to the balloon through the central lumen of the dilating catheter during balloon inflation. Regional wall motion during PTCA was assessed by simultaneous continuous two-dimensional echocardiography and was quantified by computer analysis. During control inflations accompanied by no intracoronary infusion or by transcatheter infusion of Ringer's lactate solution or nonoxygenated Fluosol DA 20%, there was profound regional left ventricular dysfunction with a greater than 90% decrease in regional contraction. In contrast, regional contraction during transcatheter infusion of oxygenated Fluosol DA 20% remained at normal levels throughout balloon inflation. Distal infusion of Fluosol DA 20% during balloon inflation is a useful adjunct to PTCA, allowing longer inflation times and perhaps permitting PTCA to be performed safely in patients with significant myocardium at ischemic risk or with limited left ventricular reserve for whom the procedure is currently believed to be too hazardous.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943533     DOI: 10.1161/01.cir.74.3.555

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Myocardial protection during coronary angioplasty.

Authors:  J J Whalen
Journal:  Tex Heart Inst J       Date:  1992

2.  Myocardial protection during coronary angioplasty.

Authors:  P Angelini; D R Leachman; G Disciascio; M J Cowley; J A Brinker
Journal:  Tex Heart Inst J       Date:  1992

3.  Use of an oxygen-carrying blood substitute to improve intravascular optical coherence tomography imaging.

Authors:  Khiet C Hoang; Ahmad Edris; Jianping Su; David S Mukai; Sari Mahon; Artiom D Petrov; Morton Kern; Chowdhury Ashan; Zhongping Chen; Bruce J Tromberg; Jagat Narula; Matthew Brenner
Journal:  J Biomed Opt       Date:  2009 May-Jun       Impact factor: 3.170

Review 4.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

Review 5.  [Artificial oxygen carriers as an alternative to red blood cell transfusion].

Authors:  O Habler; A Pape; J Meier; B Zwissler
Journal:  Anaesthesist       Date:  2005-08       Impact factor: 1.041

6.  HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute.

Authors:  S R Snyder; E V Welty; R Y Walder; L A Williams; J A Walder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

7.  Phagocytic activation of human neutrophils by the detergent component of fluosol.

Authors:  D A Ingram; M B Forman; J J Murray
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.